Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer

R Kelly; A Anton; S Wong; J Shapiro; A Weickhardt; A Azad; EM Kwan; L Spain; A Muthusamy; J Torres; P Parente; F Parnis; J Goh; A Joshua; D Pook; O Baenziger; P Gibbs; B Tran

Journal article

Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer

R Kelly, A Anton, S Wong, J Shapiro, A Weickhardt, A Azad, EM Kwan, L Spain, A Muthusamy, J Torres, P Parente, F Parnis, J Goh, A Joshua, D Pook, O Baenziger, P Gibbs, B Tran

BJU International | WILEY | Published : 2021

DOI: 10.1111/bju.15364

Download PDF

Abstract

Objectives: To investigate the recent real-world use of first-generation antiandrogens (FGAs) in metastatic castration-resistant prostate cancer (mCRPC) using a retrospective multicentre cohort study. Patients and Methods: The electronic CRPC Australian Database (ePAD) was interrogated to identify patients with mCRPC. Clinicopathological features, treatment and outcome data, stratified by FGA use, were retrieved and reported through descriptive statistics. Survival analyses were calculated using the Kaplan–Meier method and groups compared using log-rank tests. Factors influencing overall survival (OS) were analysed using Cox proportional hazards regression model. Results: We identified 634 p..

View full abstract